Free Trial

Dyne Therapeutics (DYN) Stock Price, News & Analysis

Dyne Therapeutics logo
$9.23 -1.23 (-11.76%)
Closing price 04/1/2025 04:00 PM Eastern
Extended Trading
$9.22 -0.01 (-0.11%)
As of 04:01 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Dyne Therapeutics Stock (NASDAQ:DYN)

Key Stats

Today's Range
$9.17
$10.71
50-Day Range
$9.23
$16.76
52-Week Range
$9.17
$47.45
Volume
8.27 million shs
Average Volume
1.40 million shs
Market Capitalization
$1.04 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$47.46
Consensus Rating
Buy

Company Overview

Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

Remove Ads

Dyne Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
61st Percentile Overall Score

DYN MarketRank™: 

Dyne Therapeutics scored higher than 61% of companies evaluated by MarketBeat, and ranked 417th out of 930 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Dyne Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.07, and is based on 12 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Dyne Therapeutics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Dyne Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Dyne Therapeutics are expected to decrease in the coming year, from ($3.44) to ($3.62) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Dyne Therapeutics is -2.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Dyne Therapeutics is -2.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Dyne Therapeutics has a P/B Ratio of 6.19. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Dyne Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    15.35% of the float of Dyne Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Dyne Therapeutics has a short interest ratio ("days to cover") of 6.2.
  • Change versus previous month

    Short interest in Dyne Therapeutics has recently increased by 6.08%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Dyne Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Dyne Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    15.35% of the float of Dyne Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Dyne Therapeutics has a short interest ratio ("days to cover") of 6.2.
  • Change versus previous month

    Short interest in Dyne Therapeutics has recently increased by 6.08%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Dyne Therapeutics has a news sentiment score of 0.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.77 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 7 news articles for Dyne Therapeutics this week, compared to 6 articles on an average week.
  • Search Interest

    Only 1 people have searched for DYN on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • MarketBeat Follows

    Only 2 people have added Dyne Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Dyne Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $77,760.00 in company stock.

  • Percentage Held by Insiders

    20.77% of the stock of Dyne Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    96.68% of the stock of Dyne Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Dyne Therapeutics' insider trading history.
Receive DYN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Dyne Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

DYN Stock News Headlines

Sensei Biotherapeutics (SNSE) Gets a Buy from Oppenheimer
Crypto Genius: 12,000% in 12 months? [Here’s how]
We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.
See More Headlines

DYN Stock Analysis - Frequently Asked Questions

Dyne Therapeutics' stock was trading at $23.56 at the start of the year. Since then, DYN stock has decreased by 60.8% and is now trading at $9.23.
View the best growth stocks for 2025 here
.

Dyne Therapeutics, Inc. (NASDAQ:DYN) released its quarterly earnings data on Tuesday, March, 4th. The company reported ($0.88) earnings per share for the quarter, beating analysts' consensus estimates of ($0.92) by $0.04.

Dyne Therapeutics (DYN) raised $175 million in an initial public offering on Thursday, September 17th 2020. The company issued 10,300,000 shares at a price of $16.00-$18.00 per share. JPMorgan, Jefferies, Piper Sandler and Stifel served as the underwriters for the IPO.

Shares of DYN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Dyne Therapeutics investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Netflix (NFLX) and Palo Alto Networks (PANW).

Company Calendar

Last Earnings
3/04/2025
Today
4/01/2025
Next Earnings (Estimated)
5/01/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:DYN
Previous Symbol
NYSE:DYN
Employees
100
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$47.46
High Stock Price Target
$66.00
Low Stock Price Target
$17.00
Potential Upside/Downside
+414.2%
Consensus Rating
Buy
Rating Score (0-4)
3.07
Research Coverage
15 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-235,940,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$1.49 per share
Price / Book
6.19

Miscellaneous

Free Float
80,629,000
Market Cap
$1.04 billion
Optionable
Optionable
Beta
1.11
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

This page (NASDAQ:DYN) was last updated on 4/2/2025 by MarketBeat.com Staff
From Our Partners